Board of directors

Thomas Pollare
Thomas Pollare
Chairman and member of the board since 2017.

Born: 1953

Education/experience: Thomas Pollare holds an M.D. from Karolinska Institutet and a Ph.D. from Uppsala University. He was previously a partner in the Venture Capital company 3i. He has held VP positions at both Pharmacia Corp and Schering-Plough Inc. He has been responsible for the market approval of several pharmaceutical products in various therapeutic areas and which generated billions in annual sales. He has previous experience of board work in both start-up companies and private equity investments.

Current assignments: Chairman of the Board and CEO of Oncolution AB. Chairman of the Boards of AC Intressenter AB, Sinfonia Biotherapeutics AB, AlzeCure Discovery AB, Stiftelsen AlzeCure and A3P Biomedical AB. Member of the boards of SSI Diagnostics Holding A/S och Psilox AB. Alternate member of the board of BioWorks Technologies AB.

Completed assignments (past five years): Chairman of the boards of BioWorks Technologies AB, QuiaPEG Pharmaceuticals AB and QuiaPEG Pharmaceuticals Holding AB. Member of the boards of Pharmaceuticals Sales & Development Sweden AB, Cereno Scientific AB, Premacure Holding AB, Premacure AB, Xellia Pharmaceuticals ApS, Centro Gamma Knife Santiago S.a.P Chile, Gamma Knife Center Ecuador S.APT and GammaKnife Center Indonesia.

Holding: 881,887 shares and 35,000 share options.

Dependent in relation to the company and company management, but independent in relation to the company’s largest shareholders.

Ellen Donnelly
Ellen Donnelly
Board member since 2018.

Born: 1974

Education/experience: Ellen Donnelly has a Ph.D. from Yale University Medical School (USA). Ellen has previously held various executive positions in clinical development, project management, research and strategy at Pfzer. Prior to joining Pfzer, Ellen held various positions in American biotechnology and management consultancy companies. Ellen was recently CEO of Modus Therapeutics, a Swedish biotech company that focuses on sickle cell diseases.

Current assignment: CEO, Abliva AB.

Completed assignments (past five years): CEO of Modus Therapeutics Holding AB (publ) and Modus Therapeutics AB. CEO, Epigenetics Division of Juvenescence; CEO, Souvien Therapeutics.

Holding: No shareholding.

Independent in relation to the company, company management and the company’s major shareholders

Ragnar Linder
Ragnar Linder
Board member since 2017.

Born: 1953

Education/experience: Ragnar Linder has a Master of Science degree in Chemical Engineering from KTH Royal Institute of Technology. Ragnar is a co-founder of Pygargus, a research company in the field of realworld evidence, which was bought by IMS Health (currently IQVIA) in 2013 and in which Ragnar has held senior positions ever since. He has also held several senior positions in Amgen Nordic (CEO), Aventis, HMR and Hoechst. Ragnar has also been a member of the boards of several biotech, pharmaceutical and CRO companies. Today, Ragnar is an independent consultant.

Current assignments: Member of the board of Pharmacolog i Uppsala AB.

Completed assignments (last five years): Senior Principle, Iqvia Inc. and member of the board of R. Linder Holding AB.

Holding: 30, 429 shares and 25,000 share options.

Independent in relation to the company, company management and the company’s major shareholders.

Pirkko Sulila Tamsen
Pirkko Sulila Tamsen
Board member since 2018.

Born: 1959

Education/experience: Pirkko Sulila Tamsen has a Ph.D. in zoophysiology and an MSc in biology and chemistry from Uppsala University. Pirkko is an owner and consultant in Arandi Innovation AB. Pirkko has broad commercial and drug development experience from international pharmaceutical companies such as Astra (now Astra Zeneca) and Kabi (now Pfzer), as well as in the capacity of CEO and partner of a clinical contract research company and CEO of several drug development companies.

Current assignment: Member of the boards of rebro Universitet Holding AB and rebro Universitet Enterprise AB. Chairman of the Board and CEO at Arandi Innovation AB. Alternate member of the board and deputy CEO at Arandi Development AB. CEO at OncoZenge AB.

Completed assignments (past five years): Chairman of the Board of Curenc AB and Rapp AB. Member of the boards of Karolinska Institutet Innovations AB, Örebro universitet Uppdrag AB, HepaPredict AB and C26 Bioscience AB.

Holding: 21,000 shares and 25,000 share options.

Independent in relation to the company, company management and the company’s major shareholders.

Holdings in AlzeCure Pharma AB as of December 31, 2020.